ACT initiates enrollment in TEMPASURE cardiac ablation catheter CE Mark clinical trial
Links shared publicly online about this topic.
- 433total visits
ACT initiates enrollment in TEMPASURE cardiac ablation catheter CE Mark clinical trial
Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that the first patients have been enrolled in a first-in-man CE Mark clinical trial of the safety and performance of the company's TEMPASURE™ cardiac ablation catheter. The TEMPASURE system is the world's first RF cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology.
View full resource at news-medical.net
Tags: Heart, Clinical Trial, Safety
Most Recently Shared on March 17, 2011 at 2:33 pm By:
ACT initiates enrollment in TEMPASURE cardiac ablation catheter CE Mark clinical trial: Advanced Cardiac Therape... http://bit.ly/fitQSR
Advertisement
